Pfizer Inc. (PFE) Shares Outstanding: 5.68
Is Pfizer Inc.’s shares outstanding high or low?
Pfizer Inc.'s shares outstanding of 5.68 is in line with its 5-year average of 5.63, near the high end of its 5-year range (5.55–5.68).
The shares outstanding for Pfizer Inc. (PFE) is 5.68. It is above its 12-month average by 0.17% (5.67).
PFE Shares Outstanding Chart
PFE Average Shares Outstanding Chart
PFE Current vs Average Shares Outstanding Chart
PFE Shares Outstanding Metrics
SHARES OUTSTANDING
5.68
SHARES OUTSTANDING AVG TTM
5.67
SHARES OUTSTANDING AVG 3Y
5.65
SHARES OUTSTANDING AVG 5Y
5.63
SHARES OUTSTANDING AVG 10Y
5.77
SHARES OUTSTANDING AVG 15Y
6.24
SHARES OUTSTANDING AVG 20Y
6.44
CURRENT VS TTM AVG
+0.17%
CURRENT VS 3Y AVG
+0.59%
CURRENT VS 5Y AVG
+1.02%
CURRENT VS 10Y AVG
-1.45%
CURRENT VS 15Y AVG
-8.97%
CURRENT VS 20Y AVG
-11.69%
Share Structure
Shares Outstanding
5.68B
Float Shares
N/A
Stock Price
$25.66
Market Cap
$146.4B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 5.68B | +0.33% |
| 2024 | 5.66B | +0.37% |
| 2023 | 5.64B | +0.62% |
| 2022 | 5.61B | +0.12% |
| 2021 | 5.60B | +0.83% |
| 2020 | 5.55B | -0.25% |
| 2019 | 5.57B | -5.16% |
| 2018 | 5.87B | -1.64% |
| 2017 | 5.97B | -1.95% |
| 2016 | 6.09B | -1.41% |
| 2015 | 6.18B | -2.68% |
| 2014 | 6.35B | -6.85% |
| 2013 | 6.81B | -8.45% |
| 2012 | 7.44B | -4.80% |
| 2011 | 7.82B | -2.73% |
| 2010 | 8.04B | +14.69% |
| 2009 | 7.01B | +4.16% |
| 2008 | 6.73B | -2.75% |
| 2007 | 6.92B | -4.49% |
| 2006 | 7.24B | -1.62% |
| 2005 | 7.36B | -2.26% |
| 2004 | 7.53B | +4.41% |
| 2003 | 7.21B | +17.17% |
| 2002 | 6.16B | -1.33% |
| 2001 | 6.24B | +0.47% |
| 2000 | 6.21B | +1.37% |
| 1999 | 6.13B | +61.81% |
| 1998 | 3.79B | -0.77% |
| 1997 | 3.82B | +2.85% |
| 1996 | 3.71B | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
Pfizer Inc. Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Shares Outstanding FAQ
- What is the shares outstanding for Pfizer Inc. (PFE)?
- The shares outstanding for PFE stock is 5.68.
- Is Pfizer Inc.'s shares outstanding high or low?
- Pfizer Inc.'s shares outstanding of 5.68 is in line with its 5-year average of 5.63, near the high end of its 5-year range (5.55–5.68).
- What is the TTM average shares outstanding for Pfizer Inc. (PFE)?
- The TTM average shares outstanding for PFE stock is 5.67.
- What is the 3Y average shares outstanding for Pfizer Inc. (PFE)?
- The 3Y average shares outstanding for PFE stock is 5.65.
- What is the 5Y average shares outstanding for Pfizer Inc. (PFE)?
- The 5Y average shares outstanding for PFE stock is 5.63.
- What is the 10Y average shares outstanding for Pfizer Inc. (PFE)?
- The 10Y average shares outstanding for PFE stock is 5.77.
- What is the 15Y average shares outstanding for Pfizer Inc. (PFE)?
- The 15Y average shares outstanding for PFE stock is 6.24.
- What is the 20Y average shares outstanding for Pfizer Inc. (PFE)?
- The 20Y average shares outstanding for PFE stock is 6.44.
Pfizer Inc. Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-31 | 5.68 |
| 2024-12-31 | 5.66 |
| 2023-12-31 | 5.64 |
| 2022-12-31 | 5.61 |
| 2021-12-31 | 5.60 |
| 2020-12-31 | 5.55 |
| 2019-12-31 | 5.57 |
| 2018-12-31 | 5.87 |
| 2017-12-31 | 5.97 |
| 2016-12-31 | 6.09 |
| 2015-12-31 | 6.18 |
| 2014-12-31 | 6.35 |
| 2013-12-31 | 6.81 |
| 2012-12-31 | 7.44 |
| 2011-12-31 | 7.82 |
| 2010-12-31 | 8.04 |
| 2009-12-31 | 7.01 |
| 2008-12-31 | 6.73 |
| 2007-12-31 | 6.92 |
| 2006-12-31 | 7.24 |
| 2005-12-31 | 7.36 |
| 2004-12-31 | 7.53 |
| 2003-12-31 | 7.21 |
| 2002-12-31 | 6.16 |
| 2001-12-31 | 6.24 |
| 2000-12-31 | 6.21 |
| 1999-12-31 | 6.13 |
| 1998-12-31 | 3.79 |
| 1997-12-31 | 3.82 |
| 1996-12-31 | 3.71 |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla